Related Experiment Video
Updated: Feb 3, 2026

Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022
Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis
Jimin Yuan1, Wan Hwa Ng1, Zizi Tian2
1Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Drive, 169610 Singapore, Singapore.
Abstract:
RAS-RAF-MEK-ERK signaling has a well-defined role in cancer biology. Although aberrant pathway activation occurs mostly upstream of the kinase MEK, mutations in MEK are prevalent in some cancer subsets. Here, we found that cancer-related, activating mutations in MEK can be classified into two groups: those that relieve inhibitory interactions with the helix A region and those that are in-frame deletions of the β3-αC loop, which enhance MEK1 homodimerization. The former, helix A-associated mutants, are inhibited by traditional MEK inhibitors. However, we found that the increased homodimerization associated with the loop-deletion mutants promoted intradimer cross-phosphorylation of the activation loop and conferred differential resistance to MEK inhibitors both in vitro and in vivo. MEK1 dimerization was required both for its activation by the kinase RAF and for its catalytic activity toward the kinase ERK. Our findings not only identify a previously unknown group of MEK mutants and provide insight into some key steps in RAF-MEK-ERK activation but also have implications for the design of therapies targeting RAS-ERK signaling in cancers.
Insights
Activating mutations in MEK1, a key cancer signaling protein, fall into two groups. Some MEK1 mutants resist traditional inhibitors due to increased homodimerization, impacting cancer therapy design.
Area of Science:
- Molecular Biology
- Cancer Biology
- Signal Transduction
Background:
- The RAS-RAF-MEK-ERK signaling pathway is crucial in cancer development.
- While pathway activation often occurs upstream of MEK, MEK mutations are found in certain cancers.
- Understanding MEK mutations is vital for targeted cancer therapies.
Purpose of the Study:
- To classify cancer-related activating MEK mutations.
- To investigate the mechanisms of MEK activation and resistance to inhibitors.
- To explore the role of MEK dimerization in signaling and drug response.
Main Methods:
- Biochemical assays to analyze MEK1 mutants.
- In vitro and in vivo studies of MEK inhibitor efficacy.
- Analysis of MEK1 homodimerization and cross-phosphorylation.
Main Results:
- Cancer-associated MEK mutations were categorized into two groups: helix A interaction disruptors and β3-αC loop deletion mutants.
- Loop-deletion mutants exhibit enhanced MEK1 homodimerization, leading to activation loop cross-phosphorylation.
- These homodimerization-dependent mutants show resistance to conventional MEK inhibitors.
- MEK1 dimerization is essential for RAF-mediated activation and ERK phosphorylation.
Conclusions:
- Identified a novel class of MEK mutants driven by homodimerization.
- Elucidated key steps in RAF-MEK-ERK pathway activation.
- Findings have implications for developing novel therapies against RAS-ERK signaling in cancers.
More Related Videos
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
The Eukaryotic Promoter Region
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms

